Archived Content


Day 1  |  Day 2 

Diabetes Drug Discovery Brochure 

Download Agenda 


Join scientific colleagues for discussions around risks and progress in the field of type 2 diabetes drug discovery and development. From podium presentations, an 'expert' panel session, roundtable breakout discussions and networking opportunities you will be able to:

-Keep abreast of progress on SGLT2 inhibitors and other anti-diabetes drug candidates
-Ask questions of panelists discussing 'Diabetes Drug Development Challenges'
-Learn about gastric by-pass proteins and other new targets for diabetes drugs
-Participate and problem-solve in a small group discussion on a focused topic of interest to you

Please also join us for a special dinner short course* on Targeting Pancreatic Islets for Type 2 Diabetes(click here), one of the newest areas of diabetes research, which takes place on the evening of the first day of the meeting, Nov. 3rd.

*separate registration required

THURSDAY, NOVEMBER 3

 

Diabetes Drug Development from
Different Vantages
 

1:30 pm Chairperson's Remarks

Rebecca Taub, M.D., CEO, Madrigal Pharmaceuticals

 

1:40 FEATURED PRESENTATION:

Inhibiting Glucose Transporters via SGLT inhibitors – the Next New Diabetes Drug Family?

Michael MarkMichael Mark, Ph.D., Vice President, CardioMetabolic Diseases Research, Boehringer Ingelheim

This presentation will provide an update on diabetes drug candidates in late stage development, with a focus on compounds targeting sodium glucose transporters. Current challenges faced in the field of diabetes drug development will also be covered. 

 

2:25 FEATURED PRESENTATION:

Diabetes Drug Targets from Gastric Bypass Surgery

Lee KaplanLee M. Kaplan, M.D., Ph.D., Professor, Harvard Medical School

3:10 Networking Refreshment Break in the Exhibit Hall with Poster Viewing

3:45 A Physician’s Perspective on the Future of Diabetes Treatments

Rohit KulkarniRohit N. Kulkarni, M.D., Ph.D., Associate Professor, Medicine, Harvard Medical School; Investigator, Joslin Diabetes Center

This presentation will discuss the scope of the global diabetes problem and which types of diabetes treatments are most needed from a diabetes physician’s and his patients’ perspective to help provide a relevant context to scientists developing new diabetes treatments.

Sponsored by
Taconic_NEW
4:15 Preclinical Research Models of Diabetes and Their Use in Efficacy Assessment of Therapeutics
David S. Grass, Ph.D., Vice President, Scientific Operations, Taconic
To address the challenges facing the biopharmaceutical industry, Taconic was one of the first to develop and validate a broad, in vivo focused platform, which utilizes cost-efficient mice to comprehensively characterize drug development candidates and/or genetic targets. One of the strengths of this program is the ability to characterize genetic targets and potential therapeutics impacting metabolic disorders.  Specifically, a variety of models exist for diabetes, simulating the disease condition by affecting various glucoregulatory pathways.

4:30 A GLP1 Positive Allosteric Modulators Approach for the Treatment of Type-2 Diabetes

Guillaume Duvey, Ph.D., Group Leader, Medicinal Chemistry, Addex Pharmaceuticals

4:45 Diabetes Market Landscape

Kelly Close, MBA, President, Close Concerns

 

5:15 Panel Discussion: Diabetes Drug Development

Moderator: Rebecca TaubRebecca Taub, M.D., CEO, Madrigal Pharmaceuticals
 

Panelists:

Kelly Close, MBA, President, Close Concerns

Rohit N. Kulkarni, M.D., Ph.D., Associate Professor, Medicine, Harvard Medical School; Investigator, Joslin Diabetes Center

Lee M. Kaplan, M.D., Ph.D., Professor, Harvard Medical School

Cristina Rondinone, Ph.D., Vice President, R&D, Head, Cardiovascular/Metabolic Diseases, MedImmune

 

  • Developing diabetes drugs in Asia – how is it different? Is that the future?
  • What will clinical trials look like five years from now?
  • What is the ideal diabetes treatment regimen?
 

5:45 End of Day


Please also join us for a special dinner short course* on Targeting Pancreatic Islets for Type 2 Diabetes(click here), one of the newest areas of diabetes research, which takes place on the evening of the first day of the meeting, Nov. 3rd.

*separate registration required

 

Day 1  |  Day 2 |  Download Agenda 

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag 


2014 Discovery on Target Brochure  

 green arrow FINAL BROCHURE 

PREMIER SPONSOR 

Cellecta 

green arrow VIEW ALL SPONSORS 

green arrow VIEW MEDIA PARTNERS 


SPONSORSHIPS & EXHIBITS 

The exhibit hall was sold out in 2013, so please contact us early to reserve your place. To customize your sponsorship or exhibit package for 2014, contact:

Jon Stroup
Business Development Manager
781-972-5483
jstroup@healthtech.com 

2014 Discovery On Target CAG 

green arrow CONFERENCE-AT-A-GLANCE 


CONFERENCES


October 8 – 9

Targeting Epigenetic Readers and
Chromatin Remodelers
 

Targeting the Ubiquitin Proteasome System  

Big Data Analytics and Solutions  

GPCR-Based Drug Discovery  

RNAi for Functional Genomics Screening
– Part 1
 

Protein-Protein Interactions as Drug Targets  

Antibodies Against Membrane Protein Targets
– Part 1
 


October 9 – 10

Targeting Histone Methyltransferases and Demethylases  

Screening Drug Transporter Proteins  

Maximizing Efficiency in Discovery  

GPCR-Targeted Therapeutics  

Genome Editing for Functional Genomics
Screens – Part 2
 

Cancer Metabolism  

Antibodies Against Membrane Protein Targets
– Part 2
 


SYMPOSIUM


October 7

Next Generation Histone Deacetylase Inhibitors  


SHORT COURSES


October 7

SC1: Designing Scalable Software Systems for Big Data Analytics  

SC2: Approaches for Biologically-Relevant Chemical Diversity  

SC3: Setting Up Effective RNAi Screens: From Design to Data to Validation  

SC4: Targeting Protein-Protein Interactions  

SC5: GPCR Structure-Based Drug Discovery  

SC6: Advances in Metagenomic Drug Discovery for New Anti-Infective Agents  

SC7: Targeting of GPCRs with Monoclonal Antibodies  

SC8: A Primer to Gene Editing: Tools and Applications  

SC9: Introduction to Targeted Covalent Inhibitors  


October 9

SC10: Setting Up Effective Functional Screens Using 3D Cell Cultures  

SC11: Integration of BDDCS and Extended Clearance Principles  

SC12: Introduction to Allosteric Modulators and Biased Ligands of GPCRs  

SC13: Introduction to Drug Metabolism